Jan 28, 2021 / 02:00PM GMT
Matthew Calistri - Cerevel Therapeutics Holdings, Inc. - VP of IR
Good morning, and welcome to Cerevel's first R&D event. Thank you for joining us. I'm Matthew Calistri, Vice President of Investor Relations. (Operator Instructions)
Before we begin, I'll make the following disclaimer. During the presentation, we will make certain forward-looking statements that reflect our current views related to our financial performance, future events and industry and market conditions as well as forward-looking statements, including the potential attributes and benefits of Cerevel's product candidates and the format and timing of Cerevel's product development activities and clinical trials. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. We strongly encourage you to review the information that Cerevel files with the SEC regarding specific risks and uncertainties.
I'll now turn it over to Tony Coles, Chairman and CEO of Cerevel Therapeutics. Thank you.
N. Anthony Coles - Cerevel Therapeutics
Cerevel Therapeutics Holdings Inc R&D Event Transcript
Mar 02, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers